1. Scrip

Sosei Backs RNA Activation Through Sizeable Equity And Option Deal

 
• By Sukaina Virji

MiNA hopes the equity investment and acquisition option agreement secured from Sosei results in a 'Heptares-style' arrangement with the Japanese firm.

RNA technology has failed to live up to its early drug discovery potential, but Sosei believes MiNA Therapeutics' 'activating' RNA approach could change all that.

Sosei has agreed to make a strategic investment of £35m into MiNA Therapeutics in return for a 25.6% equity share...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip